Revolution Medicines, Inc.
RVMD
Positions held
Your positionsRVMD isn't in your positions.
Add it to see shares, cost, and P&L here.
Bull / bear case
Site-generated summary from fundamentals, news, and score — not investment advice. As of 2026-10-08.
- Revolution Medicines is positioned in the rapidly growing biotechnology sector, focusing on innovative cancer therapies that address unmet medical needs.
- The company's market cap stands at approximately $42.84 billion, indicating strong investor interest and confidence in its future potential.
- Despite recent losses, RVMD's stock has a target mean price of $258.79, suggesting significant upside potential from its current valuation.
- The company has not generated any revenue in recent quarters, which raises concerns about its sustainability and ability to fund operations.
- Revolution Medicines reported a net income loss of $644.37 million in Q2 2026, continuing a trend of negative earnings over multiple quarters.
- With a profit margin of 0.0% and a debt-to-equity ratio of 45.68, RVMD faces financial challenges that could impact its growth prospects.
Fundamentals
| Market cap | $40.32B | Enterprise value | $37.57B | Trailing P/E | — | Forward P/E | -32.95 |
| PEG | — | Price / book | 15.46 | Beta | 1.40 | Dividend yield | 0.00% |
| Revenue growth | — | Earnings growth | — | Gross margin | 0.0% | Operating margin | 0.0% |
| Profit margin | 0.0% | ROE | -79.1% | ROA | -30.1% | Debt / equity | 0.46 |
| Current ratio | 11.38 | Free cash flow | -$711.61M | Analyst recommendation | strong_buy | Mean target | $259.18 |
| 52w high | $224.31 | 52w low | $47.28 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | — |
| Op margin | — | — | — | — | — | — |
| Net income | -$644M | -$454M | -$365M | -$305M | -$248M | — |
| Gross margin | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$505M | -$445M | -$362M | -$315M | -$265M | — |
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $11.6M | $35.4M |
| Op margin | — | — | -4207.1% | -730.0% |
| Net income | -$1.1B | -$600M | -$436M | -$249M |
| Gross margin | — | — | — | — |
| Gross profit | — | — | — | — |
| Operating income | -$1.2B | -$690M | -$487M | -$258M |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-08 · RBC Raises Price Target on Revolution Medicines to $259 From $251, Keeps Outperform Rating
2026-10-07 · First-Line RAS G12D Pancreatic Cancer Trial Launch Could Be A Game Changer For Revolution Medicines (RVMD)
2026-10-06 · Biotech Stocks Tumble, With Recent Winners Moderna, Vaxcyte Among The Biggest Losers
2026-10-05 · Revolution Medicines Begins Phase 3 Trial of Rasonque Combination in Pancreatic Cancer
2026-09-28 · Revolution Medicines Seen Having 'Strong' Rasonque Launch in Pancreatic Cancer, UBS Says
2026-09-28 · KRAS Inhibitor Market Projected to Reach $7.8 Billion by 2034
2026-09-25 · Can IDEAYA Biosciences (IDYA) Turn Uncharted Oncology Territory Into Commercial Gold?
2026-09-25 · Is Buying Royalty Pharma Stock a Safer Way to Bet on Revolution Medicines?
2026-09-23 · Is Revolution Medicines (RVMD) Cheap After Its FDA Breakthrough Therapy Win?
2026-09-23 · Revolution Medicines (RVMD) Deepens RAS(ON) Bet With Breakthrough PDAC Combo – But Is Risk Repricing?
2026-09-22 · Revolution Medicines (RVMD) Wins FDA Breakthrough Status For RASONQUE
Price (daily)
Full chart · RSI · MACD · patterns